Wealthspire Advisors LLC Acquires 437 Shares of Gilead Sciences, Inc. $GILD

Wealthspire Advisors LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 19.5% during the 2nd quarter, Holdings Channel.com reports. The fund owned 2,681 shares of the biopharmaceutical company’s stock after purchasing an additional 437 shares during the quarter. Wealthspire Advisors LLC’s holdings in Gilead Sciences were worth $297,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in GILD. Portside Wealth Group LLC lifted its holdings in shares of Gilead Sciences by 3.7% in the second quarter. Portside Wealth Group LLC now owns 17,455 shares of the biopharmaceutical company’s stock valued at $1,935,000 after purchasing an additional 621 shares in the last quarter. Empowered Funds LLC grew its holdings in Gilead Sciences by 0.3% during the second quarter. Empowered Funds LLC now owns 220,129 shares of the biopharmaceutical company’s stock worth $24,406,000 after buying an additional 625 shares in the last quarter. Vanguard Group Inc. raised its position in Gilead Sciences by 1.6% in the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock valued at $13,233,912,000 after buying an additional 1,893,401 shares during the last quarter. Greykasell Wealth Strategies Inc. bought a new position in Gilead Sciences during the 2nd quarter valued at $169,000. Finally, Invenio Wealth Partners LLC bought a new position in Gilead Sciences during the 2nd quarter valued at $370,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Truist Financial reiterated a “buy” rating and issued a $145.00 target price (up previously from $127.00) on shares of Gilead Sciences in a report on Monday, November 3rd. UBS Group upped their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research report on Friday, August 8th. Needham & Company LLC boosted their target price on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Finally, TD Cowen lifted their price target on Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $130.87.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $126.64 on Friday. The company has a market capitalization of $157.12 billion, a P/E ratio of 25.23, a P/E/G ratio of 0.81 and a beta of 0.32. The business has a fifty day simple moving average of $118.48 and a two-hundred day simple moving average of $113.65. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a 1 year low of $88.57 and a 1 year high of $128.70.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter in the prior year, the company earned $2.02 EPS. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be given a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s payout ratio is 48.99%.

Insider Buying and Selling at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total value of $1,193,900.00. Following the completion of the transaction, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $125.23, for a total transaction of $313,075.00. Following the sale, the chief financial officer directly owned 154,555 shares in the company, valued at $19,354,922.65. The trade was a 1.59% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 125,146 shares of company stock valued at $15,148,441. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.